Exelixis
EXEL
#1704
Rank
NZ$17.16 B
Marketcap
$60.10
Share price
-0.65%
Change (1 day)
58.67%
Change (1 year)
Exelixis, Inc. is an American genomics-based drug discovery company and the producer of Cometriq, a treatment for medullary thyroid cancer.

Exelixis (EXEL) - Total assets

Total assets on the balance sheet as of September 2024 : NZ$5.26 Billion

According to Exelixis's latest financial reports the company's total assets are NZ$5.26 Billion. A companyโ€™s total assets is the sum of all current and non-current assets, such as inventories, cash and cash equivalents, properties and equipment.

Exelixis - Total assets on balance sheet (from 2001 to 2024)

Total assets by year

Year Total assets Change
2023-12-31NZ$4.65 B-3.83%
2022-12-31NZ$4.83 B26.3%
2021-12-31NZ$3.83 B29.31%
2020-12-31NZ$2.96 B5.8%
2019-12-31NZ$2.79 B32.05%
2018-12-31NZ$2.12 B129.8%
2017-12-31NZ$0.92 B7.28%
2016-12-31NZ$0.86 B77.11%
2015-12-31NZ$0.48 B17.69%
2014-12-31NZ$0.41 B-32.63%
2013-12-31NZ$0.61 B-30.13%
2012-12-31NZ$0.87 B73.96%
2011-12-31NZ$0.50 B7.75%
2010-12-31NZ$0.46 B-1.09%
2009-12-31NZ$0.47 B-31.68%
2008-12-31NZ$0.69 B28.63%
2007-12-31NZ$0.53 B-4.14%
2006-12-31NZ$0.56 B15.3%
2005-12-31NZ$0.48 B19.22%
2004-12-31NZ$0.40 B-25.82%
2003-12-31NZ$0.55 B-15.06%
2002-12-31NZ$0.64 B-22.37%
2001-12-31NZ$0.83 B

Total Assets for similar companies or competitors

Company Total assets differencediff. Country
NZ$138.09 B 2,524.37%๐Ÿ‡ฌ๐Ÿ‡ง UK
NZ$247.25 B 4,598.71%๐Ÿ‡ซ๐Ÿ‡ท France
NZ$208.92 B 3,870.30%๐Ÿ‡บ๐Ÿ‡ธ USA
NZ$166.50 B 3,064.23%๐Ÿ‡บ๐Ÿ‡ธ USA
NZ$161.55 B 2,970.08%๐Ÿ‡บ๐Ÿ‡ธ USA
NZ$316.92 B 5,922.64%๐Ÿ‡บ๐Ÿ‡ธ USA
NZ$390.13 B 7,314.03%๐Ÿ‡บ๐Ÿ‡ธ USA
NZ$75.49 M-98.57%๐Ÿ‡บ๐Ÿ‡ธ USA
NZ$0.17 B-96.58%๐Ÿ‡บ๐Ÿ‡ธ USA